BACKGROUND Monotherapy with a P2Y12 inhibitor after a minimum period of dual antiplatelet therapy is an emerging approach to reduce the risk of bleeding after percutaneous coronary intervention (PCI). METHODS In a double-blind trial, we examined the effect of ticagrelor alone as compared with ticagrelor plus aspirin with regard to clinically relevant bleeding among patients who were at high risk for bleeding or an ischemic event and had undergone PCI. After 3 months of treatment with ticagrelor plus aspirin, patients who had not had a major bleeding event or ischemic event continued to take ticagrelor and were randomly assigned to receive aspirin or placebo for 1 year. The primary end point was Bleeding Academic Research Consortium (BARC) type 2, 3, or 5 bleeding. We also evaluated the composite end point of death from any cause, nonfatal myocardial infarction, or nonfatal stroke, using a noninferiority hypothesis with an absolute margin of 1.6 percentage points. RESULTS We enrolled 9006 patients, and 7119 underwent randomization after 3 months. Between randomization and 1 year, the incidence of the primary end point was 4.0% among patients randomly assigned to receive ticagrelor plus placebo and 7.1% among patients assigned to receive ticagrelor plus aspirin (hazard ratio, 0.56; 95% confidence interval [CI], 0.45 to 0.68; P<0.001). The difference in risk between the groups was similar for BARC type 3 or 5 bleeding (incidence, 1.0% among patients receiving ticagrelor plus placebo and 2.0% among patients receiving ticagrelor plus aspirin; hazard ratio, 0.49; 95% CI, 0.33 to 0.74). The incidence of death from any cause, nonfatal myocardial infarction, or nonfatal stroke was 3.9% in both groups (difference,-0.06 percentage points; 95% CI,-0.97 to 0.84; hazard ratio, 0.99; 95% CI, 0.78 to 1.25; P<0.001 for noninferiority). CONCLUSIONS Among high-risk patients who underwent PCI and completed 3 months of dual antiplatelet therapy, ticagrelor monotherapy was associated with a lower incidence of clinically relevant bleeding than ticagrelor plus aspirin, with no higher risk of death, myocardial infarction, or stroke.

Ticagrelor with or without aspirin in high-risk patients after PCI / Mehran, R.; Baber, U.; Sharma, S. K.; Cohen, D. J.; Angiolillo, D. J.; Briguori, C.; Cha, J. Y.; Collier, T.; Dangas, G.; Dudek, D.; Dzavik, V.; Escaned, J.; Gil, R.; Gurbel, P.; Hamm, C. W.; Henry, T.; Huber, K.; Kastrati, A.; Kaul, U.; Kornowski, R.; Krucoff, M.; Kunadian, V.; Marx, S. O.; Mehta, S. R.; Moliterno, D.; Ohman, E. M.; Oldroyd, K.; Sardella, G.; Sartori, S.; Shlofmitz, R.; Steg, P. G.; Weisz, G.; Witzenbichler, B.; Han, Y.; Pocock, S.; Gibson, C. M.. - In: THE NEW ENGLAND JOURNAL OF MEDICINE. - ISSN 0028-4793. - 381:21(2019), pp. 2032-2042. [10.1056/NEJMoa1908419]

Ticagrelor with or without aspirin in high-risk patients after PCI

Sardella G.;
2019

Abstract

BACKGROUND Monotherapy with a P2Y12 inhibitor after a minimum period of dual antiplatelet therapy is an emerging approach to reduce the risk of bleeding after percutaneous coronary intervention (PCI). METHODS In a double-blind trial, we examined the effect of ticagrelor alone as compared with ticagrelor plus aspirin with regard to clinically relevant bleeding among patients who were at high risk for bleeding or an ischemic event and had undergone PCI. After 3 months of treatment with ticagrelor plus aspirin, patients who had not had a major bleeding event or ischemic event continued to take ticagrelor and were randomly assigned to receive aspirin or placebo for 1 year. The primary end point was Bleeding Academic Research Consortium (BARC) type 2, 3, or 5 bleeding. We also evaluated the composite end point of death from any cause, nonfatal myocardial infarction, or nonfatal stroke, using a noninferiority hypothesis with an absolute margin of 1.6 percentage points. RESULTS We enrolled 9006 patients, and 7119 underwent randomization after 3 months. Between randomization and 1 year, the incidence of the primary end point was 4.0% among patients randomly assigned to receive ticagrelor plus placebo and 7.1% among patients assigned to receive ticagrelor plus aspirin (hazard ratio, 0.56; 95% confidence interval [CI], 0.45 to 0.68; P<0.001). The difference in risk between the groups was similar for BARC type 3 or 5 bleeding (incidence, 1.0% among patients receiving ticagrelor plus placebo and 2.0% among patients receiving ticagrelor plus aspirin; hazard ratio, 0.49; 95% CI, 0.33 to 0.74). The incidence of death from any cause, nonfatal myocardial infarction, or nonfatal stroke was 3.9% in both groups (difference,-0.06 percentage points; 95% CI,-0.97 to 0.84; hazard ratio, 0.99; 95% CI, 0.78 to 1.25; P<0.001 for noninferiority). CONCLUSIONS Among high-risk patients who underwent PCI and completed 3 months of dual antiplatelet therapy, ticagrelor monotherapy was associated with a lower incidence of clinically relevant bleeding than ticagrelor plus aspirin, with no higher risk of death, myocardial infarction, or stroke.
2019
aged; aspirin; coronary disease; double-blind method; drug therapy, combination; female; hemorrhage; humans; kaplan-meier estimate; male; middle aged; mortality; myocardial infarction; platelet aggregation inhibitors; risk factors; stroke; ticagrelor; percutaneous coronary intervention
01 Pubblicazione su rivista::01a Articolo in rivista
Ticagrelor with or without aspirin in high-risk patients after PCI / Mehran, R.; Baber, U.; Sharma, S. K.; Cohen, D. J.; Angiolillo, D. J.; Briguori, C.; Cha, J. Y.; Collier, T.; Dangas, G.; Dudek, D.; Dzavik, V.; Escaned, J.; Gil, R.; Gurbel, P.; Hamm, C. W.; Henry, T.; Huber, K.; Kastrati, A.; Kaul, U.; Kornowski, R.; Krucoff, M.; Kunadian, V.; Marx, S. O.; Mehta, S. R.; Moliterno, D.; Ohman, E. M.; Oldroyd, K.; Sardella, G.; Sartori, S.; Shlofmitz, R.; Steg, P. G.; Weisz, G.; Witzenbichler, B.; Han, Y.; Pocock, S.; Gibson, C. M.. - In: THE NEW ENGLAND JOURNAL OF MEDICINE. - ISSN 0028-4793. - 381:21(2019), pp. 2032-2042. [10.1056/NEJMoa1908419]
File allegati a questo prodotto
File Dimensione Formato  
Mehran_Ticagrelor_2019.pdf

solo gestori archivio

Tipologia: Versione editoriale (versione pubblicata con il layout dell'editore)
Licenza: Tutti i diritti riservati (All rights reserved)
Dimensione 389.47 kB
Formato Adobe PDF
389.47 kB Adobe PDF   Contatta l'autore

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11573/1497970
Citazioni
  • ???jsp.display-item.citation.pmc??? 152
  • Scopus 658
  • ???jsp.display-item.citation.isi??? 591
social impact